Cheryl Corcoran, MD
Program Leader in Psychosis Risk
Department of Psychiatry
Icahn School of Medicine, Mount Sinai Hospital
Cheryl Corcoran, MD is a graduate of Harvard College and Harvard Medical School. She completed her internship and residency in adult psychiatry at The Cambridge Health Alliance, a T32 fellowship in Schizophrenia Research at Columbia University, and a masters in biostatistics (Patient-Oriented Research track) at the Mailman School of Public Health.
Dr. Corcoran is Associate Professor of Psychiatry and Program Leader in Psychosis Risk at the Icahn School of Medicine at Mount Sinai.
Dr. Corcoran’s main area of expertise is in early stages of schizophrenia, including the clinical high risk (CHR) state for psychosis and first episode psychosis (FEP). Her research has included ethics and phenotypic characterization, including the use of automated natural language processing (NLP) methods to characterize disturbance in language across stages of schizophrenia, in collaboration with Dr. Guillermo Cecchi of IBM. Dr. Corcoran co-developed the Structured Interview for Prodromal Syndromes/Scale of Prodromal Symptoms (SIPS/SOPS) in 1999, and founded a prospective prodromal cohort study in 2005. She has authored 89 manuscripts on schizophrenia, with > 50 on the schizophrenia prodrome (36 first- or last-authored), encompassing automated speech analyses, sensory processing, social cognition, neuroimaging, clinical correlates, cannabis/stress exposures, nosology, stigma and ethics.
Presentation: Can Schizophrenia Be Prevented?
Dr. Corcoran will present an update on prodromal research, including operationalization of the attenuated psychosis syndrome, predictors of schizophrenia onset and functional outcome, and preventive interventions.
• Learn how to identify the clinical risk syndrome for psychosis
• Describe cognitive markers of psychosis risk, including language disturbance
• Know the evidence base for preventive intervention, and targets for intervention